Gapping up
In reaction to strong earnings/guidance:
- UNXL +6.7%, BKS +5.7%, ALXN +5.6%, (files previously delayed Form 10-Q; Audit / Finance Committee concluded that the previously issued financial results do not require restatement)
- PLCE +1.9%, AR +0.7%, (capital budget for 2017 is $1.5 billion, including $1.3 billion for drilling and completion and $200 million for core leasehold additions and extensions; Net production is expected to average 2,160 to 2,250 MMcfe/d in 2017, representing year-over-year growth of 20% to 25% relative to 2016 guidance),
M&A news:
- CEB +21.2% (to be acquired by Gartner (IT) for $2.6 billion in cash and stock)
Select oil/gas related names showing strength:
- AUY +3.6%, AG +3.1%, GDX +2.1%, ABX +2.1%, GG +2%, NEM +1.8%, GLD +1.1%
Other news:
- PIRS +28.6% (Pieris Pharmaceuticals and Servier to jointly pursue several bispecific therapeutic programs including its' proprietary dual checkpoint inhibitor PRS-332; co to receive $31.3 mln upfront, up to $539 mln in success-based payments )
- CTIC +24.7% (FDA removes full clinical hold for Pacritinib )
- KOOL +17.2% (eceives FDA approval for significant revisions to its pivotal study for treatment of Critical Limb Ischemia )
- HALO +15.5% (announces phase 2 study in advanced pancreas cancer meets key endpoints in topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its HALO 202 study)
- GNCA +13.7% (announces 'positive' clinical results from a planned interim analysis of its ongoing placebo-controlled Phase 2b trial evaluating GEN-003 )
- SHLD +10.8% (after closing near highs of the day +7%),
- SYN +10% (announces 'positive' topline data from its Phase 2b clinical trial for SYN-004; met its primary endpoint of significantly reducing C. difficile Infection)
- ARNA +6% (Arena Pharm sells all of its rights to develop and market lorcaserin to Eisai for a reduced amount than previously announced; enters into equity distribution agreement to sell & issue $50 mln in shares of common stock with Citigroup Global Markets)
- RT +3.7% (continued strength)
- GALE +3.4% (provided a corporate and clinical outlook for 2017 and announced that Mark W. Schwartz President and CEO will give a company presentation at the Biotech Showcase 2017),
Analyst comments:
- EVOK +12.3% (upgraded to Buy at Rodman & Renshaw; tgt raised to $6)
- SGYP +2.1% (initiated with a Outperform at Oppenheimer)